A successful year with many firsts.
“With ongoing revenue growth, a record EBITDA margin, an increased revenue share of high-value solutions and our inclusion in the MDAX, 2024 was a year of ground-breaking innovations and one of steady progress on expansion projects and of ever-stronger partnerships. These achievements provide a solid foundation for continued success in the year ahead.”
Andreas Reisse
SCHOTT Pharma CEO
Thinking ahead.
Pushing boundaries.
-
2024 was another year of both quantitative and qualitative growth for SCHOTT Pharma. Revenue increased by 12% on a constant-currency basis compared with the previous financial year – a new record that falls within the upper half of our guidance. We are especially proud that this growth was fuelled by high-value solutions, which saw an impressive 22% increase and now account for as much as 55% of our total revenue.
-
Our profitability improved once again despite the significant ramp-up costs that were incurred by our substantial investments in capacity expansion. On a constant-currency basis, we achieved a record margin of 27.8%. At the same time, our EBITDA grew by 17% year-on-year, also at constant currencies.
-
Our high-margin, high-value solutions (HVS) now account for 55% of our revenue. HVS are tailored to meet even the most specific customer requirements for drug contain-ment and delivery, adding exceptional value for our customers. By capitalizing on market drivers, we aim to further increase the revenue share of HVS and have made further major investments throughout the year 2024.
-
Our business has a strong cash generation: free cash flow rose significantly to EUR 79m – a testament to our operational strength. While the strong operating cash flow more than covered the considerable growth investments we made to expand our capacities, the strong free cash flow enabled us to reduce net debt by around 20%.